399 related articles for article (PubMed ID: 26615577)
1. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study.
Shah E; Reuber M; Goulding P; Flynn C; Delanty N; Kemp S
Seizure; 2016 Jan; 34():1-5. PubMed ID: 26615577
[TBL] [Abstract][Full Text] [Related]
2. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
[TBL] [Abstract][Full Text] [Related]
3. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours.
Maurousset A; Limousin N; Praline J; Biberon J; Corcia P; De Toffol B
Epilepsy Behav; 2016 Aug; 61():237-241. PubMed ID: 27393930
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study.
Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T
Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
[TBL] [Abstract][Full Text] [Related]
9. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK).
Flores L; Kemp S; Colbeck K; Moran N; Quirk J; Ramkolea P; von Oertzen TJ; Nashef L; Richardson MP; Goulding P; Elwes R
Seizure; 2012 Sep; 21(7):512-7. PubMed ID: 22698379
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Asian experience of using perampanel in clinical practice.
Chiang HI; Lim SN; Hsieh HY; Cheng MY; Chang CW; Johnny Tseng WE; Li HT; Lin CY; Wu T
Biomed J; 2017 Dec; 40(6):347-354. PubMed ID: 29433838
[TBL] [Abstract][Full Text] [Related]
12. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
[TBL] [Abstract][Full Text] [Related]
13. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy.
Gil-Nagel A; Burd S; Toledo M; Sander JW; Lebedeva A; Patten A; Laurenza A;
Seizure; 2018 Jan; 54():61-66. PubMed ID: 29288911
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
19. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
[TBL] [Abstract][Full Text] [Related]
20. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
